| 背景 | Clone IB11 is a recombinant human IgG1 Kappa antibody directed against the FMC63 idiotype, the antigen-binding specificity most widely used in CD19-targeted CAR-T constructs. Rather than binding CD19 directly, this clone is an anti-idiotype reagent that recognizes the unique variable-region determinants of the FMC63 single-chain variable fragment (scFv). This makes it well suited to functional and translational research on CD19 CAR-T therapies, where a specific tool to detect, quantify, and track FMC63-based CAR expression on engineered T cells is essential. As a research-grade material offered at low endotoxin levels and available in bulk milligram-to-gram quantities, it supports flow cytometry, cell-based binding assays, immunoassay development, and manufacturing/quality workflows for cell-therapy programs. Its fully human IgG1 Kappa framework is convenient for pairing with standard anti-human secondary detection systems. Supplied for research use only (RUO). Because target biology and application depend on the intended use as an anti-idiotype/CAR-detection reagent, confirm suitability for your specific assay format.
FMC63 is a murine monoclonal antibody clone whose scFv (the joined heavy- and light-chain variable domains) provides the CD19-binding specificity in the leading CD19 CAR-T therapies, including approved products for B-cell leukemias and lymphomas. Its target, CD19, is a B-lineage transmembrane glycoprotein that acts as a co-receptor for B-cell receptor signaling and is expressed from early pro-B stages through mature B cells but lost on plasma cells, making it a durable marker across most B-cell malignancies. The FMC63 idiotype itself, the set of unique variable-region determinants that define its antigen specificity, serves as a defined molecular handle. Anti-idiotype antibodies raised against FMC63 recognize these determinants specifically within the CAR scFv, enabling detection of CAR expression independent of the target antigen and supporting immunogenicity, pharmacokinetic, and cell-tracking studies for FMC63-based cell therapies. |
|---|
